Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Steven Gendreau"'
Autor:
Patrick Schöffski, Sara Cresta, Ingrid A. Mayer, Hans Wildiers, Silvia Damian, Steven Gendreau, Isabelle Rooney, Kari M. Morrissey, Jill M. Spoerke, Vivian W. Ng, Stina M. Singel, Eric Winer
Publikováno v:
Breast Cancer Research, Vol 20, Iss 1, Pp 1-12 (2018)
Abstract Background This phase Ib study (NCT00960960) evaluated pictilisib (GDC-0941; pan-phosphatidylinositol 3-kinase inhibitor) plus paclitaxel, with and without bevacizumab or trastuzumab, or in combination with letrozole, in patients with locall
Externí odkaz:
https://doaj.org/article/5ad511006b6a4dd38e247c9c83bf50cf
Autor:
Jill M. Spoerke, Steven Gendreau, Kimberly Walter, Jiaheng Qiu, Timothy R. Wilson, Heidi Savage, Junko Aimi, Mika K. Derynck, Meng Chen, Iris T. Chan, Lukas C. Amler, Garret M. Hampton, Stephen Johnston, Ian Krop, Peter Schmid, Mark R. Lackner
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-10 (2016)
Fulvestrant degrades the oestrogen receptor. Here, the authors report on a clinical trial using fulvestrant and show that mutations in the oestrogen receptor alpha gene are prevalent in circulating tumour DNA and do not influence the clinical outcome
Externí odkaz:
https://doaj.org/article/3ed6583a52b645a290a897ba20ac7a5f
Autor:
Stephanie B Greene, Angel E Dago, Laura J Leitz, Yipeng Wang, Jerry Lee, Shannon L Werner, Steven Gendreau, Premal Patel, Shidong Jia, Liangxuan Zhang, Eric K Tucker, Michael Malchiodi, Ryon P Graf, Ryan Dittamore, Dena Marrinucci, Mark Landers
Publikováno v:
PLoS ONE, Vol 11, Iss 11, p e0165089 (2016)
Genomic instability is a hallmark of cancer often associated with poor patient outcome and resistance to targeted therapy. Assessment of genomic instability in bulk tumor or biopsy can be complicated due to sample availability, surrounding tissue con
Externí odkaz:
https://doaj.org/article/47f7d2e4203249a1945c762cdb6bff0d
Autor:
Alejandro Martinez Chibly, Alice Shia, Radia Johnson, Michael S. Hwang, Marc Hafner, Ciara Metcalfe, Kalpit Shah, Michal Slyper, Chris Bolen, Sarah E. Pinder, Alastair M. Thompson, Steven Gendreau, Peter Schmid
Publikováno v:
Cancer Research. 83:PD10-06
Background: Endocrine therapy (ET) is the mainstay of ER+ BC treatment. However; up to 20% of ER+ BC tumors progress into metastatic disease and develop ET resistance, underscoring the need for combination therapies. Preclinical data suggest that com
Autor:
Mark R. Lackner, Craig Cummings, Steven Gendreau, Ling-Yuh Huw, Rebecca Suttmann, May M.Y. Liang-Chu, Mamie Yu, Junko Aimi, Charles Baudo, Vidushi Kapoor, Kathryn E. Yoh, Jill M. Spoerke, Ching-Wei Chang, Xiaoji Chen
cfDNA tumor fraction dynamics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::225eab50b3122ce04587e260653b6df9
https://doi.org/10.1158/1078-0432.22474475.v1
https://doi.org/10.1158/1078-0432.22474475.v1
Autor:
Viorel Jinga, Daniel J. Maslyar, Premal H. Patel, Ruth Riisnaes, Steven Gendreau, Han Ma, Wai Y. Chan, Na Xu, George Daniel Radavoi, Kent C. Shih, Jose Angel Arranz Arija, Albert Font, Sergio Bracarda, Christophe Massard, Daniel Nava Rodrigues, Ugo De Giorgi, Johann S. de Bono
Includes supplementary methods, figures, and tables.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d04392189dcb36c8a2d6d73fc4c435d1
https://doi.org/10.1158/1078-0432.22468467.v1
https://doi.org/10.1158/1078-0432.22468467.v1
Autor:
Mark R. Lackner, Craig Cummings, Steven Gendreau, Ling-Yuh Huw, Rebecca Suttmann, May M.Y. Liang-Chu, Mamie Yu, Junko Aimi, Charles Baudo, Vidushi Kapoor, Kathryn E. Yoh, Jill M. Spoerke, Ching-Wei Chang, Xiaoji Chen
Purpose:We developed a method to monitor copy number variations (CNV) in plasma cell-free DNA (cfDNA) from patients with metastatic squamous non–small cell lung cancer (NSCLC). We aimed to explore the association between tumor-derived cfDNA and cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31eb86c6dd4fbb499599b927038e7b6c
https://doi.org/10.1158/1078-0432.c.6528800
https://doi.org/10.1158/1078-0432.c.6528800
Autor:
Viorel Jinga, Daniel J. Maslyar, Premal H. Patel, Ruth Riisnaes, Steven Gendreau, Han Ma, Wai Y. Chan, Na Xu, George Daniel Radavoi, Kent C. Shih, Jose Angel Arranz Arija, Albert Font, Sergio Bracarda, Christophe Massard, Daniel Nava Rodrigues, Ugo De Giorgi, Johann S. de Bono
Purpose:PI3K–Akt–mTOR and androgen receptor (AR) signaling are commonly aberrantly activated in metastatic castration-resistant prostate cancer (mCRPC), with PTEN loss associating with poor prognosis. We therefore conducted a phase Ib/II study of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14e77f27f4ec7c9b569f79eefffe9f9c
https://doi.org/10.1158/1078-0432.c.6526956.v1
https://doi.org/10.1158/1078-0432.c.6526956.v1
Autor:
Aditi Qamra, Minu K. Srivastava, Eloisa Fuentes, Ben Trotter, Raymond Biju, Guillaume Chhor, James Cowan, Steven Gendreau, Webster Lincoln, Lisa McGinnis, Luciana Molinero, Namrata S. Patil, Amber Schedlbauer, Katja Schulze, Adam Stanford-Moore, Laura Chambre, Ilan Wapinski, David S. Shames, Hartmut Koeppen, Stephanie Hennek, Jane Fridlyand, Jennifer M. Giltnane, Assaf Amitai
Publikováno v:
Cancer Research. 83:5705-5705
Background: In recent years, a relationship between the tumor microenvironment (TME) and patient response to targeted cancer immunotherapy has been suggested. We applied machine-learning algorithms on H&E stained tissue to study the TME in metastatic
Autor:
Manish R. Patel, Luna Musib, Paul Conkling, Andrés Cervantes, Premal Patel, Kedan Lin, Nicholas J. Vogelzang, Ari David Baron, Johanna C. Bendell, J-C. Soria, Maha Hussain, Daniel J. Maslyar, Wai Y. Chan, Josep Tabernero, N. Xu, Steven J. Isakoff, Guillem Argiles, L. R. Molife, Han Ma, Deepak Sampath, Steven Gendreau
Publikováno v:
Scientia
Annals of oncology : official journal of the European Society for Medical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Annals of oncology : official journal of the European Society for Medical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Inhibidor d'AKT; Càncer avançat; Fase I Inhibidor de AKT; Cáncer avanzado; Fase I AKT inhibitor; Advanced cancer; Phase I Background This phase Ib study evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of the oral AKT